TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 in New York City, with both in-person and virtual options available. Bryan Kobel, CEO of TC BioPharm, will present an overview of the company's business during the conference. The event will feature over 550 corporate presentations and panels, providing investors with opportunities to learn about various companies and schedule individual meetings with management teams.
Positive
- Participation in a major investment conference, potentially increasing investor visibility
- CEO presenting company overview, indicating active engagement with investors
Negative
- None.
News Market Reaction – TCBP
On the day this news was published, TCBP gained 4.60%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
The in-person venue for the event is the Lotte New York Palace Hotel in
Bryan Kobel, CEO of TC BioPharm, will provide an overview of the Company's business during the presentation. More than 550 corporate presentations & panels are available during the event. For more information or if you are interested in scheduling an individual meeting with management, please contact the company directly at ir@tcbiopharm.com.
About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998. For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-participation-at-the-hc-wainwright-26th-annual-global-investment-conference-302239053.html
SOURCE TC BioPharm
FAQ
When and where is TC BioPharm (TCBP) participating in the H.C. Wainwright Global Investment Conference?
Who will be presenting for TC BioPharm (TCBP) at the H.C. Wainwright conference?
How can investors schedule a meeting with TC BioPharm (TCBP) management during the conference?
What type of therapies is TC BioPharm (TCBP) developing?
